Business Context and Reporting Period
Company: Pyxis Oncology, Inc. (PYXS)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: Pyxis is a clinical-stage oncology company focused on developing antibody-drug conjugates (ADCs) for solid tumors, specifically head and neck squamous cell carcinoma (HNSCC). Its lead product candidate is micvotabart pelidotin (MICVO), which targets the extradomain-B of fibronectin (EDB+FN) in the tumor microenvironment. The company has no approved products and has incurred significant losses since inception.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 | Three Months Ended June 30, 2026 |
|---|---|---|---|
| Revenue | $0 | $2,820 | $0 |
| Net Loss | $(48,618) | $(39,512) | $(25,346) |
| Net Loss Per Share (Basic/Diluted) | $(0.76) | $(0.64) | $(0.40) |
| Operating Expenses | $50,350 | $45,484 | $25,990 |
| Cash, Cash Equivalents & Marketable Securities | $33,000 | $62,108 (Dec 31, 2025) | $33,000 |
| Accumulated Deficit | $(491,795) | $(443,177) (Dec 31, 2025) | $(491,795) |
| Net Cash Used in Operating Activities | $(44,206) | $(39,798) | N/A |
Note: Revenue in the prior year period consisted of a regulatory milestone payment from a collaboration agreement. No product revenue has been generated.
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped to $0 for the six months ended June 30, 2026, compared to $2.82 million in the same period in 2025. The prior year revenue was a one-time regulatory milestone from the Simcere out-licensing agreement.
- Increased Net Loss: Net loss increased by approximately $9.1 million (23%) year-over-year for the six-month period, driven by higher operating expenses.
- Expense Growth:
- Research & Development (R&D): Increased by $1.9 million to $36.0 million, primarily due to a $5.4 million increase in MICVO program costs (clinical trials and preclinical studies), partially offset by reduced manufacturing costs.
- General & Administrative (G&A): Increased by $3.0 million to $14.3 million, driven by higher personnel-related expenses, including $1.1 million in severance costs and increased stock-based compensation.
- Liquidity Position: Cash and marketable securities decreased from $62.1 million at year-end 2025 to $33.0 million at June 30, 2026, reflecting the burn rate of clinical operations.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has expressed substantial doubt about the company's ability to continue as a going concern for one year from the filing date. Current cash resources, even after a recent financing, are insufficient to fund operations for the next 12 months without additional capital.
- Recent Financing (Subsequent Event): On July 2, 2026, the company closed a private placement raising approximately $50 million in gross proceeds (including $10 million received on June 30, 2026). This includes the issuance of common stock and warrants. Management expects these funds to support operations into the second quarter of 2027.
- Clinical Progress:
- MICVO Monotherapy: Preliminary data from Phase 1 dose expansion showed a 46% confirmed objective response rate (ORR) in heavily pre-treated HNSCC patients. A dose cap was implemented in December 2025 to address tolerability in high body weight patients.
- MICVO Combination: Phase 1/2 study with Merck's KEYTRUDA (pembrolizumab) showed a 71% ORR in early data. Updated data is expected in Q4 2026.
- Risks:
- Dependence on the success of MICVO; failure in clinical trials would materially harm the business.
- Need for substantial additional capital to fund clinical development and operations.
- Reliance on third-party manufacturers and CROs.
- Regulatory uncertainty and potential delays in approval processes.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $50 million private placement proceeds to fund operations through Q2 2027 and the likelihood of needing further dilutive financing before then.
- Clinical Data Durability: Monitor upcoming Fall 2026 and Q4 2026 data updates for MICVO, specifically regarding the impact of the new dose-capping strategy on safety and efficacy.
- Expense Trajectory: Review the trend in G&A expenses, particularly the impact of severance costs and stock-based compensation on future burn rates.
- Warrant Terms: Examine the terms of the warrants issued in the July 2026 private placement (exercise price $3.289, exercisable upon clinical data disclosure or Oct 1, 2026) for potential future dilution.
- Going Concern Status: Assess the company's ability to secure additional funding if the current capital is depleted faster than anticipated due to clinical trial costs or delays.